Amarin Corp Plc - Company Profile
Powered by
All the data and insights you need on Amarin Corp Plc in one report.
- Save hours of research time and resources with
our up-to-date Amarin Corp Plc Strategy Report
- Understand Amarin Corp Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Amarin Corp Plc (Amarin) is a pharmaceutical company which develops and commercializes medicines for cardiovascular diseases. The company's lead product, Vascepa (icosapent ethyl), is a single-molecule prescription capsule used as an adjunct to diet for the reduction of triglyceride levels in adult patients with severe hypertriglyceridemia and high triglyceride levels or mixed dyslipidemia and cardiovascular risk. Amarin is also evaluating Vascepa as an add-on therapy to reduce major cardiovascular events in an at-risk patient population on statin therapy. The company markets the product in the US through wholesalers and specialty pharmacy providers. The company has operations in Ireland, the US, Germany, Switzerland, the Uk, Italy, France and Israel. Amarin is headquartered at Dublin, Ireland.
Amarin Corp Plc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Vascepa Capsules | Vascepa |
Pipeline Programs: | |
Vascepa: | |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In August, the company entered into a marketing and commercialization agreement with Neopharm Israel for VAZKEPA (icosapent ethyl) in Israel and the territories of the Palestinian authority. |
2023 | Contracts/Agreements | In July, the company entered into an agreement with Lotus Pharmaceuticals to distribute and commercialize VAZKEPA. |
2023 | Contracts/Agreements | In February, the company and Seqirus announced Exclusive License and Distribution agreement for Vazkepa. |
Competitor Comparison
Key Parameters | Amarin Corp Plc | AbbVie Inc | GSK plc | Acasti Pharma Inc | Apotex Inc |
---|---|---|---|---|---|
Headquarters | Ireland | United States of America | United Kingdom | Canada | Canada |
City | Dublin | North Chicago | Brentford | Laval | Toronto |
State/Province | Dublin | Illinois | England | Quebec | Ontario |
No. of Employees | 275 | 50,000 | 70,212 | 32 | 8,000 |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Per Wold-Olsen | Chairman | Executive Board | 2022 | 74 |
Patrick J. Holt | Chief Executive Officer; Director; President | Executive Board | 2023 | 51 |
Tom Reilly | Head - Global HR & Finance; Chief Financial Officer; Executive Vice President | Senior Management | 2022 | 52 |
Steven Ketchum, Ph.D. | Executive Vice President; President - Research and Development; Chief Scientific Officer | Senior Management | 2016 | 59 |
Jonathan Provoost | Executive Vice President; Chief Legal and Compliance Officer | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer